Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Escient Pharmaceuticals, Inc
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater than or equal to 16 despite stable treatment with H1 antihistamine consistent with standard of care
Must be on a stable dose of H1 antihistamine up to 4 times the approved dose per local treatment guidelines
You may not be if
Urticaria with a clear underlying etiology other than CSU
Urticaria with a clearly defined or sole trigger (chronic inducible urticaria)
Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
Clareo Health | Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
